.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,358,533

« Back to Dashboard

Details for Patent: 6,358,533

Title: Pharmaceutical excipient having improved compressibility
Abstract:A microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1% to about 20% silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other. The silicon dioxide utilized in the novel excipient has a particle size from about 1 nanometer to about 100 microns. Most preferably, the silicon dioxide is a grade of colloidal silicon dioxide.
Inventor(s): Sherwood; Bob E. (Amenia, NY), Staniforth; John H. (Bath, GB), Hunter; Edward A. (Glenham, NY)
Assignee: Edward Mendell, Co., Inc. (Patterson, NY)
Filing Date:Jan 04, 2001
Application Number:09/754,760
Claims:1. An excipient composition comprising a particulate agglomerate of microcrystalline cellulose coprocessed with from about 5.0% to about 10% by weight silicon dioxide, based on the weight of microcrystalline cellulose, said microcrystalline cellulose and silicon dioxide being in intimate association with each other and said silicon dioxide being integrated with or partially coating said microcrystalline cellulose, said silicon dioxide portion of said agglomerate being derived from a silicon dioxide having an average primary particle size from about 1 nm to about 100 .mu.m.

2. The composition of claim 1, wherein said silicon dioxide portion of said agglomerate is derived from silicon dioxide having an average primary particle size from about 5 nm to about 40 .mu.m.

3. The composition of claim 1, wherein said silicon dioxide portion of said agglomerate is derived from colloidal silicon dioxide.

4. The composition of claim 1, wherein said particulate agglomerates have an average particle size of from about 10 .mu.m to about 1,000 .mu.m.

5. The composition of claim 1, wherein said microcrystalline cellulose is coprocessed with about 5.0% by weight silicon dioxide, based on the weight of microcrystalline cellulose.

6. The composition of claim 5, wherein said silicon dioxide portion of said agglomerate is derived from silicon dioxide having an average primary particle size from about 5 nm to about 40 .mu.m.

7. The composition of claim 5, wherein said silicon dioxide portion of said agglomerate is derived from colloidal silicon dioxide.

8. The composition of claim 5, wherein said particulate agglomerates have an average particle size of from about 10 .mu.m to about 1,000 .mu.m.

9. The composition of claim 1, wherein microcrystalline cellulose is coprocessed with about 10% by weight said silicon dioxide, based on the weight of microcrystalline cellulose.

10. The composition of claim 9, wherein said silicon dioxide portion of said agglomerate is derived from silicon dioxide having an average primary particle size from about 5 nm to about 40 .mu.m.

11. The composition of claim 9, wherein said silicon dioxide portion of said agglomerate is derived from colloidal silicon dioxide.

12. The composition of claim 9, wherein said particle agglomerates have an average particle size of from about 10 .mu.m to about 1,000 .mu.m.

13. The composition of claim 1, wherein said particulate agglomerates have an average particle size of from about 10 .mu.m to about 500 .mu.m.

14. The composition of claim 1, wherein said particulate agglomerates have an average particle size of from about 30 .mu.m to about 250 .mu.m.

15. The composition of claim 1, wherein said particulate agglomerates have a moisture content from about 0.5% to about 15%.

16. The composition of claim 1, wherein said particulate agglomerates further comprise a member of the group consisting of non-silicon metal oxides, starches, starch derivatives, surfactants, polyalkylene oxides, celluloses, cellulose ethers, cellulose esters and mixtures thereof.

17. The composition of claim 1, wherein said silicon dioxide portion of said agglomerate is derived from silicon dioxide having a surface area from about 10 m.sup.2 /g to about 500 m.sup.2 /g.

18. The composition of claim 1, wherein said silicon dioxide portion of said agglomerate is derived from silicon dioxide having a surface area from about 175 m.sup.2 /g to about 350 m.sup.2 /g.

19. The composition of claim 1, wherein said excipient has a bulk density from about 0.2 g/ml to about 0.6 g/ml.

20. The composition of claim 3, wherein said excipient has a bulk density from about 0.35 g/ml to about 0.55 g/ml.

21. An excipient composition comprising a particulate agglomerate of microcrystalline cellulose coprocessed with from about 5.0% by weight silicon dioxide, based on the weight of microcrystalline cellulose, and microcrystalline cellulose and silicon dioxide being in intimate association with each other and said silicon dioxide being integrated with or partially coating said microcrystalline cellulose, said silicon dioxide portion of said agglomerate being derived from a silicon dioxide having an average primary particle size from about 1 nm to about 100 .mu.m.

22. An excipient composition comprising a particulate agglomerate of microcrystalline cellulose coprocessed with from about 10% by weight silicon dioxide, based on the weight of microcrystalline cellulose, said microcrystalline cellulose and silicon dioxide being in intimate association with each other and said silicon dioxide being integrated with or partially coating said microcrystalline cellulose, said silicon dioxide portion of said agglomerate being derived from a silicon dioxide having an average primary particle size from about 1 nm to about 100 .mu.m.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc